{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,11]],"date-time":"2026-06-11T18:41:15Z","timestamp":1781203275918,"version":"3.54.1"},"reference-count":28,"publisher":"MDPI AG","issue":"1","license":[{"start":{"date-parts":[[2023,1,18]],"date-time":"2023-01-18T00:00:00Z","timestamp":1674000000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Hematology Reports"],"abstract":"<jats:p>Objectives: To investigate and characterize JAK2 mutations in myelodysplastic syndrome (MDS), we present three cases with diverse JAK2 mutations and review the literature. Methods: The institutional SoftPath software was used to find MDS cases between January 2020 and April 2022. The cases with a diagnosis of a myelodysplastic\/myeloproliferative overlap syndrome including MDS\/MPN with ring sideroblasts and thrombocytosis were excluded. The cases with molecular data by next generation sequencing looking for gene aberrations commonly seen in myeloid neoplasms were reviewed for the detection of JAK2 mutations including variants. A literature review on the identification, characterization, and significance of JAK2 mutations in MDS was performed. Results: Among 107 cases of the MDS reviewed, a JAK2 mutation was present in three cases, representing 2.8% of the overall cases. A JAK2 V617F mutation was found in one case representing slightly less than 1% of all the MDS cases. In addition, we found JAK2 R564L and JAK2 I670V point mutation variants to be associated with a myelodysplastic phenotype. Conclusions: JAK2 mutations in MDS are rare and represent less than 3% of cases. It appears that JAK2 variant mutations in MDS are diverse and further studies are needed to understand their role in the phenotype and prognosis of the disease.<\/jats:p>","DOI":"10.3390\/hematolrep15010008","type":"journal-article","created":{"date-parts":[[2023,1,19]],"date-time":"2023-01-19T07:42:27Z","timestamp":1674114147000},"page":"73-87","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["JAK2 Mutations Are Rare and Diverse in Myelodysplastic Syndromes: Case Series and Review of the Literature"],"prefix":"10.3390","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8627-1802","authenticated-orcid":false,"given":"Melissa","family":"Delio","sequence":"first","affiliation":[{"name":"Department of Pathology, Beth Israel Deaconess Medical Center, Boston, MA 02215, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christine","family":"Bryke","sequence":"additional","affiliation":[{"name":"Department of Pathology, Beth Israel Deaconess Medical Center, Boston, MA 02215, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lourdes","family":"Mendez","sequence":"additional","affiliation":[{"name":"Division of Hematology\/Oncology, Beth Israel Deaconess Medical Center, Boston, MA 02215, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Loren","family":"Joseph","sequence":"additional","affiliation":[{"name":"Department of Pathology, Beth Israel Deaconess Medical Center, Boston, MA 02215, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarmad","family":"Jassim","sequence":"additional","affiliation":[{"name":"Department of Pathology, William Beaumont Hospital, Royal Oak, MI 48073, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2023,1,18]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","unstructured":"Brooks, J.A., and Putoczki, T. (2020). JAK-STAT Signalling Pathway in Cancer. Cancers, 12.","DOI":"10.3390\/cancers12071971"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"450","DOI":"10.3324\/haematol.2010.033191","article-title":"The JAK2 V617F somatic mutation, mortality and cancer risk in the general population","volume":"96","author":"Nielsen","year":"2011","journal-title":"Haematologica"},{"key":"ref_3","unstructured":"WHO (2017). Classification of Tumours of Haematopoietic and Lymphoid Tissues, IARC Press. [4th ed.]."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1111\/bjh.12099","article-title":"Diagnostic value of JAK2 V617F somatic mutation for myeloproliferative cancer in 49 488 individuals from the general population","volume":"160","author":"Nielsen","year":"2012","journal-title":"Br. J. Haematol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"2388","DOI":"10.1007\/s12032-012-0202-3","article-title":"Impaired apoptosis of megakaryocytes and bone marrow mononuclear cells in essential thrombocythemia: Correlation with JAK2V617F mutational status and cytoreductive therapy","volume":"29","author":"Trelinski","year":"2012","journal-title":"Med. Oncol."},{"key":"ref_6","doi-asserted-by":"crossref","unstructured":"Raivola, J., Haikarainen, T., Abraham, B.G., and Silvennoinen, O. (2021). Janus Kinases in Leukemia. Cancers, 13.","DOI":"10.3390\/cancers13040800"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"2601","DOI":"10.1038\/onc.2012.347","article-title":"JAK\/STAT signaling in hematological malignancies","volume":"32","author":"Vainchenker","year":"2013","journal-title":"Oncogene"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"1855","DOI":"10.1002\/cncr.31986","article-title":"Janus Kinase 2 Variants Associated with the Transformation of Myeloproliferative Neoplasms into Acute Myeloid Leukemia","volume":"125","author":"Benton","year":"2019","journal-title":"Cancer"},{"key":"ref_9","first-page":"747","article-title":"Concomitant and noncanonical JAK2 and MPL mutations in JAK2V617F- and MPLW515 L-positive myelofibrosisGenes Chromosomes","volume":"58","author":"Schulze","year":"2019","journal-title":"Cancer"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"4591","DOI":"10.1182\/blood.V110.11.4591.4591","article-title":"Analysis of JAK2 V167F Mutation in Myelodysplastic Syndromes","volume":"110","author":"Fermo","year":"2007","journal-title":"Blood"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1016\/j.leukres.2014.10.006","article-title":"The molecular basis and clinical significance of genetic mutations identified in myelodysplastic syndromes","volume":"39","author":"Zhang","year":"2015","journal-title":"Leuk. Res."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"2496","DOI":"10.1056\/NEJMoa1013343","article-title":"Clinical Effect of Point Mutations in Myelodysplastic Syndromes","volume":"364","author":"Bejar","year":"2011","journal-title":"N. Engl. J. Med."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1038\/leu.2013.336","article-title":"Landscape of genetic lesions in 944 patients with myelodysplastic syndromes","volume":"28","author":"Haferlach","year":"2014","journal-title":"Leukemia"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"e276","DOI":"10.3324\/haematol.2019.227686","article-title":"Myeloid neoplasms with isolated del(5q) and JAK2 V617F mutation: A \u201cgrey zone\u201d combination of myelodysplastic and myeloproliferative features?","volume":"105","author":"Sangiorgio","year":"2019","journal-title":"Haematologica"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"1319","DOI":"10.1038\/sj.leu.2404215","article-title":"The JAK2 V617F mutation identifies a subgroup of MDS patients with isolated deletion 5q and a proliferative bone marrow","volume":"20","author":"Ingram","year":"2006","journal-title":"Leukemia"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1182\/asheducation-2008.1.52","article-title":"The Role of JAK2 Mutations in RARS and Other MDS","volume":"2008","author":"Cazzola","year":"2008","journal-title":"Hematology"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"1283","DOI":"10.1038\/leu.2010.105","article-title":"WHO-defined \u2018myelodysplastic syndrome with isolated del(5q)\u2019 in 88 consecutive patients: Survival data, leukemic transformation rates and prevalence of JAK2, MPL and IDH mutations","volume":"24","author":"Patnaik","year":"2010","journal-title":"Leukemia"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"2359","DOI":"10.1038\/sj.leu.2403989","article-title":"The JAK2 V617F tyrosine kinase mutation in myelodysplastic syndromes (MDS) developing myelofibrosis indicates the myeloproliferative nature in a subset of MDS patients","volume":"19","author":"Ohyashiki","year":"2005","journal-title":"Leukemia"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"579221","DOI":"10.3389\/fonc.2020.579221","article-title":"Comparison and Implications of Mutational Profiles of Myelodysplastic Syndromes, Myeloproliferative Neoplasms, and Myelodysplastic\/Myeloproliferative Neoplasms: A Meta-Analysis","volume":"10","author":"Wan","year":"2020","journal-title":"Front. Oncol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1182\/blood-2005-03-1183","article-title":"The JAK2 V617F activating tyrosine kinase mutation is an infrequent event inboth \u201catypical\u201d myeloproliferative disorders and myelodysplastic syndromes","volume":"106","author":"Steensma","year":"2005","journal-title":"Blood"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1007\/s12308-008-0014-8","article-title":"The implication of identifying JAK2V617F in myeloproliferative neoplasms and myelodysplastic syndromes with bone marrow fibrosis","volume":"1","author":"Olsen","year":"2008","journal-title":"J. Hematopathol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"1165","DOI":"10.1038\/sj.leu.2404196","article-title":"The lack of association between JAK2 V617F mutation and myelodysplastic syndrome with or without myelofibrosis","volume":"20","author":"Yip","year":"2006","journal-title":"Leukemia"},{"key":"ref_23","first-page":"64","article-title":"Prognostic impact of JAK2V617F mutation in myelodysplatic syndromes: A matched case control study","volume":"2","author":"Wattel","year":"2013","journal-title":"Leuk. Res. Rep."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1056\/NEJMoa1611604","article-title":"Prognostic Mutations in Myelodysplastic Syndrome after Stem-Cell Transplantation","volume":"376","author":"Lindsley","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"ref_25","first-page":"717","article-title":"A landscape of germ line mutations in a cohort of inherited bone marrow failure patients","volume":"131","author":"Bluteau","year":"2018","journal-title":"Blood J. Am. Soc. Hematol."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"2309","DOI":"10.1182\/blood-2017-05-787390","article-title":"Germline loss-of-function SAMD9 and SAMD9L alterations in adult myelodysplastic syndromes","volume":"132","author":"Nagata","year":"2018","journal-title":"Blood"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"1106","DOI":"10.1038\/s41375-018-0074-4","article-title":"SAMD9 and SAMD9L in inherited predisposition to ataxia, pancytopenia, and myeloid malignancies","volume":"32","author":"Davidsson","year":"2018","journal-title":"Leukemia"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1002\/ajh.22180","article-title":"Janus Kinase V617F mutation in cigarette smokers","volume":"87","author":"Weinberg","year":"2011","journal-title":"Am. J. Hematol."}],"container-title":["Hematology Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2038-8330\/15\/1\/8\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T18:09:31Z","timestamp":1760119771000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2038-8330\/15\/1\/8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,1,18]]},"references-count":28,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,3]]}},"alternative-id":["hematolrep15010008"],"URL":"https:\/\/doi.org\/10.3390\/hematolrep15010008","relation":{},"ISSN":["2038-8330"],"issn-type":[{"value":"2038-8330","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,1,18]]}}}